## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

1. (Original) A compound of the formula (I)

wherein

D is a radical selected from the group comprising heterocyclic and homocyclic rings, X is a radical selected from the group comprising, C=O, SO<sub>2</sub>, NH-(C=O), (C=O)-NH, C=S, CH<sub>2</sub>, O-(C=O), (C=O)-O, (C=S)-NH, NH-(C=S), NR<sup>a</sup>-(C=O), (C=O)-NR<sup>a</sup>, (C=S)-NR<sup>a</sup> and NR<sup>a</sup>-(C=S),

Y is a radical selected from the group comprising  $-(CH_2)_n$ -E- $(CH_2)_m$ -L- $(CH_2)_k$  and  $-(CH_2)_m$ -L- $(CH_2)_k$ ,

wherein E is a radical selected from the group comprising O, S and NR<sup>b</sup>, k, m and n are individually and independently 0, 1, 2 and 3,

Z is a radical selected from the group comprising C=O, and alkyl, whereby preferably alkyl is CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>,

A is a radical selected from the group comprising benzyl, substituted benzyl, phenyl, substituted phenyl, alkyl and substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, substituted heterocyclylalkyl, substituted heterocyclylalkyl, substituted heterocyclylalkyl, alkyloxy-alkyl, substituted alkyloxy-alkyl, alkyloxy-cycloalkyl,

substituted alkyloxy-cycloalkyl, alkyloxy-heterocyclyl, substituted alkyloxy-heterocyclyl, alkyloxy-aryl, substituted alkyloxy-heteroaryl, substituted alkyloxy-heteroaryl, alkylthio-alkyl, substituted alkylthio-alkyl, alkylthio-cycloalkyl and substituted alkylthio-cycloalkyl,

B is a radical having formula (II)

$$H$$
 COOH  $Q-R_2$   $R_1$   $H$  (II)

wherein

R<sub>1</sub> is selected from the group comprising H, benzyl, substituted benzyl, phenyl, substituted phenyl, alkyl and substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted cycloalkylalkyl, eycloalkylalkyl, substituted cycloalkylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, alkyloxy-alkyl, substituted alkyloxy-alkyl, alkyloxy-cycloalkyl, substituted alkyloxy-heterocyclyl, substituted alkyloxy-heterocyclyl, substituted alkyloxy-heteroaryl, alkyloxy-aryl, alkyloxy-heteroaryl, substituted alkyloxy-heteroaryl, alkylthio-alkyl, alkylthio-cycloalkyl and substituted alkylthio-cycloalkyl,

R<sub>2</sub> is selected from the group comprising H, benzyl, substituted benzyl, phenyl, substituted phenyl, alkyl and substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, alkyloxy-alkyl, substituted alkyloxy-alkyl, alkyloxy-cycloalkyl,

substituted alkyloxy-cycloalkyl, alkyloxy-heterocyclyl, substituted alkyloxy-heterocyclyl, alkyloxy-aryl, substituted alkyloxy-aryl, alkyloxy-heteroaryl, substituted alkyloxy-heteroaryl, alkylthio-alkyl, substituted alkylthio-alkyl, alkylthio-cycloalkyl and substituted alkylthio-cycloalkyl,

G is a radical comprising at least one nitrogen atom, and

wherein Q and L are each and independently from each other a radical selected from the group comprising (C=O)-NH, C=O, C=S, NH, O, S, CH<sub>2</sub>, NH-NH, N=N, CH=N, N=CH, NH-(C=O)-NH, NH-(C=O), O-(C=O)-NH, NH-(C=O)-O, (C=O)-O, O-(C=O), NH-(C=S), (C=S)-NH, NH-(C=S)-NH, SO<sub>2</sub>, NH-SO<sub>2</sub>, SO<sub>2</sub>-NH, NR<sup>c</sup>, (C=O)-NR<sup>c</sup>, NR<sup>c</sup>, NR<sup>c</sup>-(C=O)-NH, NH-(C=O)-NR<sup>c</sup>, NR<sup>c</sup>-(C=O)-NR<sup>d</sup>, NR<sup>c</sup>-(C=O), O-(C=O)-NR<sup>c</sup>, NR<sup>c</sup>-(C=O)-O, NR<sup>c</sup>-(C=S)-NR<sup>c</sup>, NR<sup>c</sup>-(C=S)-NH, NH-(C=S)-NR<sup>c</sup>, NR<sup>c</sup>-(C=S)-NR<sup>d</sup>, NR<sup>c</sup>-SO<sub>2</sub> and SO<sub>2</sub>-NR<sup>c</sup>, and

wherein any of R<sup>a</sup>, R<sup>b</sup>, R<sup>c</sup> and R<sup>d</sup> is each and independently a radical selected from the group comprising H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycloyl, substituted heterocycloyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, alkyloxy-alkyl, substituted alkyloxy-alkyl, alkyloxy-cycloalkyl, substituted alkyloxy-heterocyclyl, substituted alkyloxy-heterocyclyl, alkyloxy-aryl, substituted alkyloxy-heteroaryl, substituted alkyloxy-heteroaryl, alkylthio-alkyl, substituted alkylthio-cycloalkyl and substituted alkylthio-cycloalkyl.

2. (Original) The compound according to claim 1, wherein the ring in D is an aromatic or a non-aromatic ring.

- 3. (Currently Amended) The compound according to claim 1 er-2, wherein the ring in D is selected from the group comprising five-membered rings, six-membered rings, seven-membered rings, eight-membered rings, nine-membered rings and ten-membered rings or the ring in D is a condensed ring system selected from the group comprising four-four-membered rings, four-five-membered rings, five-five-membered rings, six-seven-membered rings, seven-seven-membered rings.
- 4. (Currently Amended) The compound according to any of claims 1 to 3 claim 1, wherein the ring in D is a heterocyclic ring comprising at least one nitrogen atom.
- 5. (Original) The compound according to claim 4, wherein any of X, Y, Z is attached to the nitrogen atom.
- 6. (Currently Amended) The compound according to any of claims 1 to 5 claim 1, wherein the compound is of the formula (III a, III b)

wherein o and p are independently and individually 0, 1, 2 or 3.

7. (Currently Amended) The compound according to any of claims 1 to 6 claim 1, wherein D is selected from the group comprising pyrrole, pyrrolidine, indole, pyridine, piperidine, quinoline, isoquinoline, imidazole, pyrimidine, purine, pyridazine piperazine, 1,3,5-triazine, 1,2,3-triazole, imidazolidine, and pyrazole and any derivatives of each thereof.

- 8. (Currently Amended) The compound according to any of claims 1 to 6 claim 1, wherein D is a radical selected from the group comprising thiophene, thiazole, isothiazole, 1,4 dithiane, 1,3,5 trithiane, and thiomorpholine.
- 9. (Currently Amended) The compound according to any of claims 1 to 3 claim 1, wherein D is a radical selected from the group comprising furane, dioxane, pyrane and derivatives of each thereof.
- 10. (Currently Amended) The compound according to any of claims 1 to 3 claim 1, wherein D is a radical selected from the group comprising oxazole, isoxazole, and thiazole and derivatives of each thereof.
- 11. (Currently Amended) The compound according to any of claims 1 to 10 claim 1, wherein

n is 0, E is O, m is 1, L is (C=O)-NH and k is 0; or n is 1, E is O, m is 1, L is (C=O)-NH and k is 0; or n is 0, E is O, m is 2, L is (C=O)-NH and k is 0; or n is 0, E is  $CH_2$ , m is 1, L is (C=O)-NH and k is 0; or n is 1, E is O, m is 2, L is (C=O)-NH and k is 0.

- 12. (Currently Amended) The compound according to any of claims 1 to 11 claim 1, wherein Z is CH<sub>2</sub>.
- 13. (Currently Amended) The compound according to any of claims 1 to 12 claim 1, wherein A is selected from the group comprising alkyl and substituted alkyl, cycloalkyl, substituted cycloalkyl, alkyloxy-alkyl, substituted alkyloxy-alkyl, alkylthio-alkyl, substituted alkylthio-alkyl, alkylthio-alkyl, substituted alkylthio-alkyl, alkylthio-cycloalkyl and substituted alkylthio-cycloalkyl.


- 14. (Currently Amended) The compound according to any of claims 1 to 12 claim 1, wherein A is selected from the group comprising benzyl, substituted benzyl, phenyl, substituted phenyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, arylalkyl substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, alkyloxy-heterocyclyl, substituted alkyloxy-heterocyclyl, alkyloxy-aryl, substituted alkyloxy-aryl, alkyloxyheteroaryl, substituted alkyloxy-heteroaryl, arylthio-alkyl, substituted arylthio-alkyl, arylthio-cycloalkyl and substituted arylthio-cycloalkyl.
- (Currently Amended) 15. The compound according to any of claims 1 to 12 and 14 claim 1, wherein A is a phenyl derivative or a benzyl derivative having the formula (IV) or (V)

$$R_3$$
 $R_4$ 
 $R_5$ 
 $R_4$ 
 $R_5$ 
 $R_4$ 
 $R_5$ 

wherein R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> is each and independently a radical selected from the group comprising H, halogen, alkyl, substituted alkyl, alkoxy and substituted alkoxy.

16. The compound according to claim 15, wherein alkyl is selected (Original) from the group comprising methyl, ethyl, propyl, butyl, pentyl, hexyl, whereby any of the residues is straight, branched, branched-linear or branched non-linear.

- Page 9
- The compound according to claim 15 or 16, 17. (Currently Amended) wherein alkoxy is selected from the group comprising methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy.
- The compound according to claim 15, wherein the substituted 18. (Original) alkyl is an alkyl ha(Currently Amended) ving at least one halogen, NO<sub>2</sub>, OH, CN residue.
- The compound according to claim 18, wherein the substituted 19. (Original) alkyl is selected from the group comprising CF<sub>3</sub> and CCl<sub>3</sub>.
- The compound according to any of claims 1 to 13 20. (Currently Amended) claim 1, wherein A is a linear alkyl or non-linear alkyl, preferable A is 2,2-dimethylbutyl.
- (Currently Amended) The compound according to any of claims 15 to 20 21. claim 15, wherein the halogen is independently selected from the group comprising I, Br, Cl and F.
- The compound according to any of claims 1 to 21 22. (Currently Amended) claim 1, wherein R2 is selected from the group comprising alkyl and substituted alkyl, cycloalkyl, substituted cycloalkyl, alkyloxy-alkyl, substituted alkyloxy-alkyl, alkyloxycycloalkyl, substituted alkyloxy-cycloalkyl, alkylthio-alkyl, substituted alkylthio-alkyl, alkylthio-cycloalkyl and substituted alkylthio-cycloalkyl, more preferably selected from the group comprising cycloalkyl and substituted cycloalkyl, and more preferably R<sub>2</sub> is



- 23. (Currently Amended) The compound according to any of claims 1 to 21 claim 1, wherein R<sub>2</sub> is selected from the group comprising benzyl, substituted benzyl, phenyl, substituted phenyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, alkyloxy-heterocyclyl, substituted alkyloxy-heterocyclyl, alkyloxy-aryl, substituted alkyloxy-aryl, alkyloxy-heteroaryl, substituted arylthio-alkyl, substituted arylthio-alkyl, arylthio-cycloalkyl and substituted arylthio-cycloalkyl.
- 24. (Currently Amended) The compound according to any of claims 1 to 23 claim 1, wherein R<sub>2</sub> is a radical having the following formula (VI)

wherein q is 0, 1, 2, 3, or 4,

R<sub>6</sub>, R<sub>7</sub> and R<sub>8</sub> are each individually and independently selected from the group of radicals comprising halogen, alkyl, substituted alkyl, alkoxy and substituted alkoxy.

- 25. (Original) The compound according to claim 24, wherein alkyl and/or the substituted alkyl is selected from the group comprising methyl, ethyl, propyl, butyl, pentyl, hexyl, whereby any of the residues is straight, branched, branched-linear or branched non-linear.
- 26. (Currently Amended) The compound according to claims 23 or 24 23, wherein alkoxy is selected from the group comprising methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy.
- 27. (Currently Amended) The compound according to claim 24 and 25, wherein the substituted alkyl is an alkyl having at least one halogen NO<sub>2</sub>, OH, CN residue.
- 28. (Original) The compound according to claim 27, wherein the substituted alkyl is selected from the group comprising CF<sub>3</sub> and CCl<sub>3</sub>.
- 29. (Original) The compound according to claim 24, wherein R<sub>2</sub> is mesitylene.
- 30. (Currently Amended) The compound according to any of claims 1 to 29 claim 1, wherein Q of B is C=O.
- 31. (Currently Amended) The compound according to any of claims 1 to 29 claim 1, wherein Q of B is SO<sub>2</sub>.
- 32. (Currently Amended) The compound according to any of claims 1 to 31 claim 1, wherein G is a radical of formula (VII).

wherein R<sub>9</sub> is a heterocyclic ring and r is 0, 1, 2, 3 or 4.

- 33. (Original) The compound according to claim 32, wherein  $R_7$  is a three-membered, four-membered, five-membered, six-membered, seven-membered, eight-membered, nine-membered or ten-membered ring, preferably having at least one nitrogen atom in the ring.
- 34. (Original) The compound according to claim 32, wherein  $R_7$  is a condensed ring, preferably having at least one nitrogen atom.
- 35. (Currently Amended) The compound according to any of claims 1 to 31 claim 1 wherein G is a guanidine radical.
- 36. (Currently Amended) The compound according to any of claims 1 to 34 claim 1, wherein G is (C=O)-NH<sub>2</sub> or NH-(C=O)-NH<sub>2</sub>.
- The compound according to any of claims 1 to 31 claim 1, wherein G is selected from the group comprising pyridin-2-ylamine, pyrimidin-2-ylamine, 1(2) *H*-imidazol-2-ylamine, 4,5-dihydro-1*H*-imidazol-2-ylamine, 1,4,5,6-tetrahydro-pyrimidin-2-ylamine, 4,5,6,7-tetrahydro-1*H*-[1,3]diazepin-2-ylamine, 1,4,5,6,7,8-hexahydro-[1,3]diazocine, 1,4,5,6,7,8,9,10-octahydro-[1,3]diazecin-2-ylamine, 4,5-dihydro-3*H*-pyrrol-2-ylamine, 3,4,5,6-tetrahydro-pyridin-2-ylamine, 4,5,6,7-tetrahydro-3*H*-azepin-2-ylamine, 3,4,5,6,7,8-hexahydro-azocin-2-ylamine, 3,4,5,6,7,8,9,10-octahydro-azecin-2-ylamine, 1*H*-benzoimidazol-2-ylamine, 2(3)*H*-pyrazol-3-ylamine, 1*H*-indol-2-ylamine, 1,2,3,4-tetrahydro-[1,8]naphthyridine, pyrazin-2-ylamine and any derivative of each thereof, whereby preferably such derivative is selected from the group comprising the alkyl derivative, the alkoxy derivative, the thioalkyl derivative and the halogen derivative.

38. (Currently Amended) The compound according to any of claims 1 to 31 claim 1, wherein G is selected from the group comprising pyridin-2-ylamine, 4-methoxy-pyridin-2-ylamine, 1(2)*H*-imidazol-2-ylamine, 2(3)*H*-pyrazol-3-ylamine.

39 (Currently Amended) A compound having the formula (VIII)

wherein  $R_{10}$  is  $-CO-R_{13}$  or  $-CO-O-R_{13}$ , wherein  $R_{11}$  is a substituted pyridine-2-ylamine, wherein  $R_{12}$  is  $-CO-R_{13}$ ,  $-SO_2-R_{13}$ , and wherein  $R_{13}$  is a radical selected from the group comprising alkyl, substituted alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl, whereby the compound is preferably a compound according to any of claims 1 to 38 claim 1.

40. (Original) The compound according to claim 39, whereby the compound has the formula (IX)

wherein  $R_{14}$  is 3,3-dimethyl-butyryl or 3-carboxy-phenyl, wherein  $R_{15}$  is pyridin-2-ylamine or 4-methoxy-pyridin-2-ylamine, wherein  $R_{16}$  is  $-CO-R_{17}$ , and wherein  $R_{17}$  is mesitylene or 1-methyl cyclohexyl,

## whereby the compound is preferably a compound according to any of claims 1 to 38.

A compound selected from the group comprising 41. (Original) [2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)compound 5: ethylcarbamoyl]-methoxy-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 2-[1-Phenylacetyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3compound 9: yloxy]-acetylamino-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid (2-Benzenesulfonylamino-2-carboxy-ethylcarbamoyl)compound 10: methoxy-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester) compound 13: 4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid butyl ester 3-{2-[1-(3-Phenyl-propionyl)-5-(pyridin-2-ylaminomethyl)compound 14: pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid 3-{2-[1-Phenylmethanesulfonyl-5-(pyridin-2compound 15: ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethylbenzenesulfonylamino)-propionic aci 3-{2-[1-(Butane-1-sulfonyl)-5-(pyridin-2-ylaminomethyl)compound 16: pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid compound 17: 3-{2-[1-Methyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid 3-{2-[1-(3-Phenyl-propyl)-5-(pyridin-2-ylaminomethyl)compound 18: pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 19:

3-{2-[5-(Pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-

compound 20:

3-{2-[1-Cyclopentylcarbamoyl-5-(pyridin-2-

ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-

benzenesulfonylamino)-propionic acid

compound 21:

3-{2-[1-Cyclohexylcarbamoyl-5-(pyridin-2-

ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-

benzenesulfonylamino)-propionic acid

compound 22:

3-{2-[1-Butylcarbamoyl-5-(pyridin-2-ylaminomethyl)-

pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic

acid

compound 23:

3-{2-[1-Pentylcarbamoyl-5-(pyridin-2-ylaminomethyl)-

pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic

acid

compound 24:

3-{2-[1-(2-Fluoro-benzylcarbamoyl)-5-(pyridin-2-

ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-

benzenesulfonylamino)-propionic acid

compound 25:

3-{2-[1-(4-Methyl-benzylcarbamoyl)-5-(pyridin-2-

ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-

benzenesulfonylamino)-propionic acid

compound 26:

3-{2-[1-Phenethylcarbamoyl-5-(pyridin-2-ylaminomethyl)-

pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic

acid

compound 27:

3-{2-[1-(3-Methyl-benzylcarbamoyl)-5-(pyridin-2-

ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-

benzenesulfonylamino)-propionic acid

compound 28:

3-{2-[1-Phenylcarbamoyl-5-(pyridin-2-ylaminomethyl)-

pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic

acid

compound 29:

3-{2-[1-(2-Methyl-pentanoyl)-5-(pyridin-2-ylaminomethyl)-

pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic

acid

compound 30:

3-{2-[1-(3-Cyclopentyl-propionyl)-5-(pyridin-2-

ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-

benzenesulfonylamino)-propionic acid

compound 31:

3-{2-[1-(3,3-Dimethyl-butyryl)-5-(pyridin-2-

ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-

benzenesulfonylamino)-propionic acid

compound 32:

3-{2-[1-Cyclohexanecarbonyl-5-(pyridin-2-

ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-

benzenesulfonylamino)-propionic acid

compound 33:

3-{2-[5-(Pyridin-2-ylaminomethyl)-1-(3,5,5-trimethyl-

hexanoyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 34:

3-{2-[5-(Pyridin-2-ylaminomethyl)-1-(2-thiophen-2-yl-

acetyl) - pyrrolidin - 3 - yloxy] - acetylamino) - 2 - (2,4,6 - trimethyl - benzenesulfonylamino) - (2,4,6 -

propionic acid

compound 35:

3-{2-[1-(2-Cyclopentyl-acetyl)-5-(pyridin-2-

ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-

benzenesulfonylamino)-propionic acid

compound 36:

3-{2-[1-[2-(3-Methoxy-phenyl)-acetyl]-5-(pyridin-2-

ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-

benzenesulfonylamino)-propionic acid

compound 37:

3-{2-[1-Isobutyryl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-

3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 38:

3-{2-[1-Propionyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-

3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 39:

3-{2-[1-(2-Phenoxy-acetyl)-5-(pyridin-2-ylaminomethyl)-

pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 40:

3-{2-[1-Benzoyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-

yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 41: 4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid isobutyl ester

compound 42: 4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid ethyl ester

compound 43: 4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid hexyl ester

compound 44: 4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid prop-2-ynyl ester

compound 45: 4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid but-3-enyl ester

compound 46: 3-{2-[1-Benzylcarbamoyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 47: 3-{2-[1-Carbamoyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 48: 3-{2-[5-(Pyridin-2-ylaminomethyl)-1-(2-trifluoromethyl-phenylcarbamoyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 49: 3-{2-[1-(Benzo[1,3]dioxol-5-ylcarbamoyl)-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 50: 3-{2-[1-(Biphenyl-4-ylcarbamoyl)-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethylbenzenesulfonylamino)-propionic acid

compound 51: 3-{2-[1-Benzylthiocarbamoyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 52: 3-{2-[1-Acetyl-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid compound 53: 4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid methyl ester

compound 54: 3-{2-[1-[2-(2-Methoxy-ethoxy)-acetyl]-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 55: 4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid 4-fluoro-benzyl ester

compound 56: 4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid 4-chloro-benzyl ester

compound 57: 3-{2-[1-[3-(4-Fluoro-phenyl)-propionyl]-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 58: 3-{2-[1-[3-(4-Chloro-phenyl)-propionyl]-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

compound 59: 4-{[2-Ethoxycarbonyl-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 60: 3-{2-[1-(3,3-Dimethyl-butyryl)-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethyl-benzoylamino)-propionic acid

compound 61: 5-{[4-{[2-Carboxy-2-(2,4,6-trimethylbenzenesulfonylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)pyrrolidine-1-carbothioyl]-amino}-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-benzoic acid compound 62: 3-{2-{1-(Anthracene-2-sulfonyl)-5-(pyridin-2ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethylbenzenesulfonylamino)-propionic acid 3-{2-[1-(2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-Pentadecafluorocompound 63: octanoyl)-5-(pyridin-2-ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6trimethyl-benzenesulfonylamino)-propionic acid compound 64: 3-{2-[1-(3,5-Bis-trifluoromethyl-benzoyl)-5-(pyridin-2ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-(2,4,6-trimethylbenzenesulfonylamino)-propionic acid 3-{2-[1-(3,3-Dimethyl-butyryl)-5-(pyridin-2compound 65: ylaminomethyl)-pyrrolidin-3-yloxy]-acetylamino}-2-[(1-methyl-cyclohexanecarbonyl)amino]-propionic acid 4-{[2-Carboxy-2-(2,4,6-trimethyl-benzoylamino)compound 66: ethylcarbamoyl]-methoxy}-2-[(4-methoxy-pyridin-2-ylamino)-methyl]-pyrrolidine-1carboxylic acid benzyl ester compound 67: 4-{[2-(Butane-1-sulfonylamino)-2-carboxyethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-[(2-Carboxy-2-phenylmethanesulfonylaminocompound 68: ethylcarbamoyl)-methoxyl-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 69: 4-[(2-Carboxy-2-methanesulfonylamino-ethylcarbamoyl)methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 70: 4-[(2-Benzoylamino-2-carboxy-ethylcarbamoyl)methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 71: 4-{[2-Carboxy-2-(2,4,6-trimethyl-benzoylamino)ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 72: 4-[(2-Carboxy-2-phenylacetylamino-ethylcarbamoyl)methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-({2-[(Biphenyl-4-carbonyl)-amino]-2-carboxycompound 73: ethylcarbamoyl}-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 74: 4-{[2-Carboxy-2-(3-phenyl-propionylamino)ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 75: 4-{[2-(3-Butyl-ureido)-2-carboxy-ethylcarbamoyl]methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 76: 4-{[2-Carboxy-2-(3-phenyl-ureido)-ethylcarbamoyl]methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-{[2-(3-Benzyl-ureido)-2-carboxy-ethylcarbamoyl]compound 77: methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 78: 4-({2-Carboxy-2-[3-(2,6-dimethyl-phenyl)-ureido]ethylcarbamoyl}-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-{[2-Carboxy-2-(3-phenethyl-ureido)-ethylcarbamoyl]compound 79: methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 80: 4-{[2-(3-Biphenyl-4-yl-ureido)-2-carboxy-ethylcarbamoyl]methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-[(2-Amino-2-carboxy-ethylcarbamoyl)-methoxy]-2compound 81: (pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 82: 4-{[2-Carboxy-2-(2,4,6-trimethyl-benzylamino)ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-{[2-Carboxy-2-(2-trifluoromethyl-benzoylamino)compound 83: ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 84: 4-{[2-Carboxy-2-(3-trifluoromethyl-benzoylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 85: 4-{[2-Carboxy-2-(4-trifluoromethyl-benzoylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 86: 4-{[2-(3,5-Bis-trifluoromethyl-benzoylamino)-2-carboxy-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 87: 4-{[2-Carboxy-2-(2-methyl-benzoylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 88: 4-{[2-Carboxy-2-(2-methoxy-benzoylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 89: 4-{[2-Carboxy-2-(4-methyl-benzoylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 90: 4-{[2-Carboxy-2-(2,6-dimethoxy-benzoylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 91: 4-{[2-Carboxy-2-(cyclohexanecarbonyl-amino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 92: 4-{[2-Carboxy-2-(2,6-dimethyl-benzoylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

compound 93: 4-{[2-Carboxy-2-(3,5-dimethyl-benzoylamino)-ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

Page 22

4-{[2-Carboxy-2-(3,4,5-trimethoxy-benzoylamino)compound 94: ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-{[2-Carboxy-2-(2-fluoro-benzoylamino)compound 95: ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 96: 4-{[2-Carboxy-2-(2-nitro-benzoylamino)-ethylcarbamoyl]methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-{[2-Carboxy-2-(2-chloro-benzoylamino)compound 97: ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-{[2-Carboxy-2-(2,6-dichloro-benzoylamino)compound 98: ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 99: 4-{[2-Carboxy-2-(2,6-difluoro-benzoylamino)ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 100: 4-({2-Carboxy-2-[(3-methyl-thiophene-2-carbonyl)amino]-ethylcarbamoyl}-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1carboxylic acid benzyl ester 4-({2-Carboxy-2-[(1-methyl-cyclohexanecarbonyl)compound 101: amino]-ethylcarbamoyl}-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1carboxylic acid benzyl ester compound 102: 4-{[2-Carboxy-2-(3-methyl-2-phenyl-butyrylamino)ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 103: 4-{[2-Carboxy-2-(2-ethyl-benzoylamino)-ethylcarbamoyl]methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 104: 4-({2-[(Biphenyl-2-carbonyl)-amino]-2-carboxyethylcarbamoyl}-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester

4-({2-Carboxy-2-[(2-methyl-cyclohexanecarbonyl)compound 105: amino]-ethylcarbamoyl}-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1carboxylic acid benzyl ester compound 106: 4-({2-Carboxy-2-[(1-phenyl-cyclopropanecarbonyl)amino]-ethylcarbamoyl}-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1carboxylic acid benzyl ester 4-({2-Carboxy-2-[(1-phenyl-cyclopentanecarbonyl)compound 107: amino]-ethylcarbamoyl}-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1carboxylic acid benzyl ester compound 108: 4-{[2-Carboxy-2-(2,2-dicyclohexyl-acetylamino)ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-{[2-Carboxy-2-(2-dimethylamino-benzoylamino)compound 109: ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-{[2-Carboxy-2-(2-difluoromethylsulfanyl-benzoylamino)compound 110: ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-{[2-Carboxy-2-(2-methyl-pentanoylamino)compound 111: ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl este 4-{[2-Carboxy-2-(3-cyclopentyl-propionylamino)compound 112: ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 113: 4-{[2-Carboxy-2-(cyclobutanecarbonyl-amino)ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-{[2-Carboxy-2-(3,3-dimethyl-butyrylamino)compound 114: ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid

benzyl ester

compound 115: 4-{[2-Carboxy-2-(3,5,5-trimethyl-hexanoylamino)ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 116: 4-[(2-Carboxy-2-propionylamino-ethylcarbamoyl)methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 117: 4-{[2-Carboxy-2-(2,2-dimethyl-propionylamino)ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-{[2-Carboxy-2-(2,2-dimethyl-butyrylamino)compound 118: ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-{[2-Carboxy-2-(cyclopropanecarbonyl-amino)compound 119: ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-{[2-Carboxy-2-(2-cyclopentyl-acetylamino)compound 120: ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-[(2-Carboxy-2-isobutyrylamino-ethylcarbamoyl)compound 121: methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 122: 4-{[2-Carboxy-2-(2-cyclohexyl-acetylamino)ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-{[2-Carboxy-2-(2-propyl-pentanoylamino)compound 123: ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-{[2-Carboxy-2-(4-methyl-pentanoylamino)compound 124: ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 125: 4-{[2-Carboxy-2-(2-cycloheptyl-acetylamino)ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid

benzyl ester

Page 25

compound 126: 4-{[2-Carboxy-2-(2,4,6-triisopropyl-benzoylamino)ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-{[2-Carboxy-2-(4-phenyl-butyrylamino)compound 127: ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-{[2-Carboxy-2-(5-phenyl-pentanoylamino)compound 128: ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 129: 2-[(1H-Benzoimidazol-2-ylamino)-methyl]-4-{[2-carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy}-pyrrolidine-1carboxylic acid benzyl ester 4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)compound 130: ethylcarbamoyl]-methoxy}-2-(pyrimidin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)compound 131: ethylcarbamoyl]-methoxy}-2-[(5-chloro-pyridin-2-ylamino)-methyl]-pyrrolidine-1carboxylic acid benzyl ester 4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)compound 132: ethylcarbamoyl]-methoxy}-2-[(2H-imidazol-2-ylamino)-methyl]-pyrrolidine-1carboxylic acid benzyl ester 4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)compound 133: ethylcarbamoyl]-methoxy}-2-(isoquinolin-3-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 134: 4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-

ethylcarbamoyl]-methoxy}-2-[(5-trifluoromethyl-pyridin-2-ylamino)-methyl]pyrrolidine-1-carboxylic acid benzyl ester compound 135: 4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)ethylcarbamoyl]-methoxy}-2-[(1H-pyrazol-3-ylamino)-methyl]-pyrrolidine-1-carboxylic

acid benzyl ester

```
compound 136:
                          4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-
ethylcarbamoyl]-methoxy}-2-[(5-methyl-pyridin-2-ylamino)-methyl]-pyrrolidine-1-
carboxylic acid benzyl ester
                          4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-
compound 137:
ethylcarbamoyl]-methoxy}-2-[(6-methyl-pyridin-2-ylamino)-methyl]-pyrrolidine-1-
carboxylic acid benzyl ester
                          2-[(6-Amino-pyridin-2-ylamino)-methyl]-4-{[2-carboxy-2-
compound 138:
(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-methoxy}-pyrrolidine-1-
carboxylic acid benzyl ester
                          4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-
compound 139:
ethylcarbamoyl]-methoxy}-2-[(4,6-dimethyl-pyridin-2-ylamino)-methyl]-pyrrolidine-1-
carboxylic acid benzyl ester
                          4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-
compound 140:
ethylcarbamoyl]-methoxy}-2-(quinolin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid
benzyl ester
compound 141:
                          4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-
ethylcarbamoyl]-methoxy}-2-[(5-phenyl-pyridin-2-ylamino)-methyl]-pyrrolidine-1-
carboxylic acid benzyl ester
compound 142:
                          4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-
ethylcarbamoyl]-methoxy}-2-[(4-methyl-pyridin-2-ylamino)-methyl]-pyrrolidine-1-
carboxylic acid benzyl ester
compound 143:
                          4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-
ethylcarbamoyl]-methoxy}-2-[(4-methoxy-pyridin-2-ylamino)-methyl]-pyrrolidine-1-
carboxylic acid benzyl ester
compound 144:
                          4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-
ethylcarbamoyl]-methoxy}-2-[(4-chloro-pyridin-2-ylamino)-methyl]-pyrrolidine-1-
carboxylic acid benzyl ester
compound 145:
                          3-(2-{1-(3,3-Dimethyl-butyryl)-5-[(4-methoxy-pyridin-2-
ylamino)-methyl]-pyrrolidin-3-yloxy}-acetylamino)-2-(2,4,6-trimethyl-
benzenesulfonylamino)-propionic acid
```

Page 27

3-(2-{1-(3,3-Dimethyl-butyryl)-5-[(4-methoxy-pyridin-2compound 146: ylamino)-methyl]-pyrrolidin-3-yloxy}-acetylamino)-2-(2,4,6-trimethyl-benzoylamino)propionic acid 4-({2-Carboxy-2-[(1-methyl-cyclohexanecarbonyl)compound 147: amino]-ethylcarbamoyl}-methoxy)-2-[(4-methoxy-pyridin-2-ylamino)-methyl]pyrrolidine-1-carboxylic acid benzyl ester 3-(2-{1-(3,3-Dimethyl-butyryl)-5-[(4-methoxy-pyridin-2compound 148: ylamino)-methyl]-pyrrolidin-3-yloxy}-acetylamino)-2-[(1-methylcyclohexanecarbonyl)-amino]-propionic acid 4-[(1-Carboxymethyl-2-methyl-propylcarbamoyl)compound 149: methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 150: 4-[(1-Carboxymethyl-2-phenyl-ethylcarbamoyl)-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 151: 4-[(2-Carboxy-1-phenyl-ethylcarbamoyl)-methoxy]-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-[(1-Carboxymethyl-2-p-tolyl-ethylcarbamoyl)-methoxy]compound 152: 2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-[(2-Carboxy-1-phenyl-ethylcarbamoyl)-methoxy]-2compound 153: (pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-{[3-Carboxy-3-(2,4,6-trimethyl-benzenesulfonylamino)compound 154: propylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester 4-({[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)compound 155: ethyl]-methyl-carbamoyl}-methoxy)-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1carboxylic acid benzyl ester 4-[(2-Carboxy-2-phenyl-ethylcarbamoyl)-methoxy]-2compound 156: (pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester compound 157: 4-{[2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)ethylcarbamoyl]-methoxy}-2-(pyridin-2-ylaminomethyl)-pyrrolidine-1-carboxylic acid benzyl ester.

- 42. (Currently Amended) Use of a compound according to any of claims 1 to 41 claim 1 as an inhibitor.
- 43. (Original) Use according to claim 42, wherein the compound is an inhibitor to an integrin.
- 44. (Original) Use according to claim 43, wherein the integrin is alpha5beta1 integrin.
- 45. (Currently Amended) Use of a compound according to any of claims 1 to 41 claim 1 for the manufacture of a medicament, preferably a medicament for the treatment and/or prevention of a disease.
- 46. (Original) Use of a compound according to claim 45, wherein the medicament is for a disease mediated by or involving alpha5beta1 integrin.
- 47. (Currently Amended) Use according to claim 45 or 46, wherein the disease is selected from the group comprising diseases based on pathological angiogenesis and/or diseases based on interaction of an integrin with a ligand, whereby preferably the ligand is present on the extracellular matrix and/or on any cell surface.
- 48. (Currently Amended) Use according to any of claims 45 to 47 claim 45, wherein the disease is related to an ocular tissue, the skin, joint, neoplasm, synovial tissue, intestinal tissue and/or the bone tissue.
- 49. (Currently Amended) Use according to any of claims 45 to 48 claim 45, wherein the disease is a disease of an ocular tissue, preferably diabetic retinopathy, retinopathy of prematurity or macular degeneration, more preferably age related macular degeneration by neovascularization.

- 50. (Currently Amended) Use according to any of claims 45 to 48 claim 45, wherein the disease is a disease of the skin, more preferably hemangioma or psoriasis.
- 51. (Currently Amended) Use according to any of claims 45 to 48 claim 45, wherein the disease is a disease of or affecting the joints, more preferably rheumatoid arthritis and/or osteoarthritis.
- 52. (Currently Amended) Use according to any of claims 45 to 48 claim 45, wherein the disease is a neoplasm, more preferably a malignant neoplasm.
- 53. (Original) Use according to claim 52, wherein the malignant neoplasm is a carcinoma, more preferably the carcinoma is selected from the group comprising breast carcinoma, ovarian carcinoma, colon carcinoma, pancreatic carcinoma, bladder carcinoma, sarcoma, mesothelioma, teratocarcinoma, astrocytoma, melanoma, angioma and glioblastoma.
- 54. (Currently Amended) Use according to any of claims 45 to 48 claim 45, wherein the disease is based on an interaction of an integrin with a ligand in the extracellular matrix or on the cell surface, preferably the disease is an inflammatory disease.
- 55. (Currently Amended) Use according to any of claims 45 to 48 claim 45, wherein the disease is based on an interaction of an integrin with a ligand in the extracellular matrix or on the cell surface, preferably the disease is an infectious disease.
- 56. (Currently Amended) Use according to any of claims 45 to 48 and 54 claim 45, wherein the inflammatory disease is a disease preferably selected from the group comprising gingivitis, inflammatory bowel disease, ulcerative colitis, Crohn's disease and coronary thrombosis.

- 57. (Currently Amended) Use according to any of claims 45 to 48 and 55 claim 45, wherein the disease is an infectious disease, more preferably the disease is an infection caused by or involving fungi, bacteria and/or viruses.
- 58. (Currently Amended) Use according to any of claims 45 to 48 and 54 claim 45, wherein the disease is a non-neoplastic cell proliferative disorder, preferably the non-neoplastic cell proliferative disorder is selected from the group comprising fibrotic disorders, more preferably the fibrotic disorder is fibrosis.
- 59. (Currently Amended) Use according to any of claims 45 to 58 claim 45, wherein the medicament is for the treatment of macular degeneration, and wherein A is selected from the group comprising alkyl and substituted alkyl, cycloalkyl, substituted cycloalkyl, alkyloxy-alkyl, substituted alkyloxy-alkyl, alkyloxy-cycloalkyl, substituted alkyloxy-cycloalkyl, alkylthio-alkyl, substituted alkylthio-alkyl, alkylthio-cycloalkyl, substituted benzyl, phenyl, substituted phenyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heterocyclylalkyl, substituted cycloalkylalkyl, heterocyclylalkyl substituted heterocyclylalkyl, alkyloxy-heterocyclyl, substituted alkyloxy-heterocyclyl, alkyloxy-aryl, substituted alkyloxy-heteroaryl, substituted alkyloxy-heteroaryl, arylthio-alkyl, substituted arylthio-alkyl, arylthio-cycloalkyl and substituted arylthio-cycloalkyl.
- 60. (Currently Amended) Use according to any of claims 45 to 59, preferably claim 59 claim 59, wherein R<sub>2</sub> is selected from the group comprising alkyl

and substituted alkyl, cycloalkyl, substituted cycloalkyl, alkyloxy-alkyl, substituted alkyloxy-alkyl, alkyloxy-cycloalkyl, substituted alkyloxy-cycloalkyl, alkylthio-alkyl, substituted alkylthio-alkyl, alkylthio-cycloalkyl and substituted alkylthio-cycloalkyl.

- 61. (Currently Amended) Use according to any of claims 45 to 60, preferably claims 59 and 60 claim 59, wherein Q of B is C=O or SO<sub>2</sub>.
- 62. (Currently Amended) Use according to any of claims 45 to 58 claim 45, wherein the medicament is for the treatment of neoplasms, and wherein A is selected from the group comprising alkyl and substituted alkyl, cycloalkyl, substituted cycloalkyl, alkyloxy-alkyl, substituted alkyloxy-alkyl, alkyloxy-cycloalkyl, substituted alkyloxy-cycloalkyl, substituted alkyloxy-cycloalkyl, alkylthio-cycloalkyl and substituted alkylthio-cycloalkyl, benzyl, substituted benzyl, phenyl, substituted phenyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, arylalkyl substituted arylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, substituted cycloalkylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, alkyloxy-heterocyclyl, substituted alkyloxy-heterocyclyl, alkyloxy-heteroaryl, substituted alkyloxy-heteroaryl, substituted alkyloxy-heteroaryl, arylthio-alkyl, substituted arylthio-cycloalkyl and substituted arylthio-cycloalkyl.

- 63. (Currently Amended) Use according to any of claims 45 to 58 and 62 claim 45, wherein R<sub>2</sub> is selected from the group comprising benzyl, substituted benzyl, phenyl, substituted phenyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, alkyloxy-heterocyclyl, substituted alkyloxy-heterocyclyl, alkyloxy-aryl, substituted alkyloxy-aryl, alkyloxyheteroaryl, substituted alkyloxy-heteroaryl, arylthio-alkyl, substituted arylthio-alkyl, arylthio-cycloalkyl and substituted arylthio-cycloalkyl.
- 64. (Currently Amended) Use according to any of claims 45 to 56 and 62 to 63, preferably claims 62 and 63 claim 62, wherein Q of B is SO<sub>2</sub> or C=O.
- Use of a compound according to any of claims 39 65. (Currently Amended) and 40 claim 39 for the manufacture of a medicament for the treatment of macular degeneration and/or neoplasms.
- Use of a compound according to any of claims 1 to 66. (Currently Amended) 41 claim 1 as a diagnostic tool or for the manufacture of a diagnostic tool, whereby preferably such diagnostic tool is useful for in vivo and/or for ex vivo application.
- 67. Use according to any of claims 42 to 66 claim 42, (Currently Amended) wherein the compound comprises a further moiety, preferably a moiety which is selected from the group comprising a targeted moiety, a delivery moiety, and a detection moiety.

- 68. (Currently Amended) Use according to claim 67, wherein the further moiety is attached, preferably conjugated, to the said compound according to any of claims 1 to 41.
- 69. (Currently Amended) Use according to claim 67 or 68, wherein the detection moiety is a label, whereby preferably the label is selected from the group comprising radionuclide labels, paramagnetic material, X-ray attenuating material, immune labels, colored labels, chemiluminescent labels, luminescent labels, fluorescent labels, enzyme substrates, enzymes, and labels complexing detectable ions.
- 70. (Currently Amended) Use according to any of claims 67 to 69 claim 67, whereby the diagnostic tool is used in an *in vivo* imaging method and/or an *ex vivo* imaging method, more particularly radionuclide imaging, positron emission tomography, computerized axial tomography, magnetic resonance imaging, luminescence, fluorescence, and chemiluminescence.
- 71. (Currently Amended) Use according to any of claims 42 to 70 claim 42, wherein the moiety is a targeted moiety, whereby targeted moiety is preferably a pharmaceutically active moiety, whereby the pharmaceutically active moiety is selected from the group comprising cytotoxins, chemotherapeutics, antibodies, radionuclides and cytotoxic proteins.
- 72. (Currently Amended) Use according to any of claims 42 to 71 claim 42, wherein the targeted moiety is selected from the group comprising antibodies, linker molecules and liposomes.
- 73. (Currently Amended) A pharmaceutical composition comprising a compound according to any of claims 1 to 41 claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

- 74. (Original) The pharmaceutical composition according to claim 73 comprising another pharmaceutically active compound.
- 75. (Currently Amended) The pharmaceutical composition according to claim 73 or 74, wherein the compound is present as a pharmaceutically acceptable salt or a pharmaceutically active solvate.
- 76. (Currently Amended) The pharmaceutical composition according to any of claims 73 to 75 claim 73, wherein the compound is either alone or in combination with any of the ingredients of the composition present in a multitude of individualised dosages and/or administration forms.
- 77. (Currently Amended) The pharmaceutical composition according to any of claims 73 to 76 claim 73 for the treatment of a disease, whereby the disease is selected from diseases mediated by or involving alpha5beta1 integrin.
- 78. (Currently Amended) The pharmaceutical composition according to any of claims 73 to 77 claim 73 for the treatment of a disease, whereby the disease is any of the diseases defined in any of claims 45 to 58 mediated by or involving alpha5beta1 integrin.
- 79. (Cancelled)
- 80. (Original) The pharmaceutical composition according to claim 79, whereby the method of treatment is selected from the group comprising chemotherapy, anti-hormone therapy, radiation therapy, photodynamic therapy, surgery, and anti-angiogenic therapy.
- 81. (Currently Amended) A method for treating an integrin associated state in a subject comprising administering to said subject an effective amount of a

compound according to any of claims 1 to 41 claim 1 such that said integrin associated state is treated.

- 82. (Original) The method according to claim 81, wherein the integrin is alpha5beta1 integrin.
- 83. (Currently Amended) A method for treating a disease in a subject comprising administering to said subject an effective amount of a compound according to any of claims 1 to 41 claim 1 such that the disease is treated.
- 84. (Currently Amended) The method according to claim 83, wherein the disease is any of the diseases defined in any of claims 45 to 58 mediated by or involving alpha5beta1 integrin.